Education
About Us
Working with TipRanks
Follow Us
Heart Test Laboratories, Inc. (HSCS)
:HSCS
HSCS Stock Chart & Stats
$3.44
-$0.05(-1.44%)
At close: 4:00 PM EST
$3.44
-$0.05(-1.44%)
Day’s Range― - ―
52-Week Range$2.52 - $6.47
Previous CloseN/A
Volume8.49K
Average Volume (3M)29.98K
Market Cap
$7.23M
Enterprise Value$3.22M
Total Cash (Recent Filing)$2.79B
Total Debt (Recent Filing)$1.95B
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Dec 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding2,647,712
10 Day Avg. Volume25,613
30 Day Avg. Volume29,979
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.05
Price to Sales (P/S)757.08
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue1.69
Enterprise Value/Gross Profit2.74
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside205.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.4
Revenue Forecast (FY)$600.00K
Bulls Say, Bears Say
Bulls Say
Market OpportunityA multi-billion-dollar opportunity exists with its cloud platform to manage hospital ECGs and provide AI disease detection.
New CustomersHeartSciences signed its first MyoVista Insights Platform customer, Westcliffe Health Innovations, in the UK.
Regulatory ApprovalsHeartSciences is setting up for a large market opportunity, with the approval of the MyoVista device expected to complement the current rollout of MyoVista Insights cloud software platform.
Bears Say
Financial RequirementsMore financing is required due to the company's cash position and quarterly burn rate, indicating a need for substantial cash to finance its expected monetization phase.
Price Target AdjustmentThe price target has been reset to $9 from $15, reflecting the impact of share-count dilution on the net present value analysis.
Revenue DelayFDA submission for the MyoVista Insights software platform is now expected to be delayed to CY1H26, pushing out initial revenue projections to late CY26.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $2.52 and its highest was $6.47 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $7.23M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Dec 11, 2025 which is in 33 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Sep 11, 2025. The company reported -$1.735 earnings per share for the quarter, the consensus estimate of -$1.735 by $0.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 2,647,712 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$1.735 in its last earnings report, expectations of -$1.735. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
Company Description
Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. (HSCS) specializes in innovative cardiac testing solutions that enhance the accuracy of heart disease diagnosis and management. Operating within the healthcare sector, the company develops and provides advanced diagnostic tools and technology, focusing on non-invasive heart testing methods. Their core products include state-of-the-art diagnostic devices and software that assist healthcare professionals in assessing cardiovascular health effectively.
HSCS Stock 12 Month Forecast
Average Price Target
$10.50
▲(205.23% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
0.47% Insiders
0.43% Mutual Funds
0.71% Other Institutional Investors
98.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---